Weekly Insights | Big Health Industry Investment & Financing Report 20240610

【Precision Blood Purification】Kangyuan Medical Technology (Dalian) Co., Ltd. was established in November 2016. The company has built a new generation of specific material development technology platform centered on nanobodies. Its main business directions include the development of Class III medical device raw materials and products for precise blood purification treatments for renal failure, liver failure, and sepsis; the screening and preparation of novel nanobodies; the development of new affinity chromatography media; and the research and production of innovative clinical diagnostic reagents. It is China's only enterprise engaged in the research and development of precise blood purification products based on nanobody technology, with technology at an internationally advanced and domestically leading level.

[Investor]Dao Tong Investment

【Brain-Computer Interface Bionic Organs】Neulink, founded in 2022, is headquartered in the Yangtze River Delta Intelligent Innovation Science Park (Wujiang District, Suzhou City) and has a research and development center in Shanghai. It focuses on the development of brain-computer interface solutions for the rehabilitation of sensory loss. The company's core R&D products are bionic eyes and bionic ears based on brain-computer interface technology, designed to replace the sensory organs of patients who are completely blind or deaf. Neulink will continue to expand the application of brain-computer interface technology into other areas of medical rehabilitation. The core founding team has deep roots in the medical device industry, possessing strong academic backgrounds and resources, with significant advantages spanning from product development, production, clinical trials, to registration and certification.

【Investor】Danlu Capital, Cofoe Healthcare

【Microfluidics】Beijing BOE Zhiwei Microbiology Technology, a strategic subsidiary of BOE Group, is an in vitro diagnostic solution provider integrating diagnostic reagents and complete equipment, with its core in independently innovated microfluidic technology. The company owns a medical-engineering integrated R&D platform for microfluidic chip design and processing, biological detection reagents, and medical testing equipment, as well as a 10,000-class cleanroom facility compliant with GMP production management standards. The company aims to become a global leader in the molecular diagnostics industry, empowering the construction of China's precision healthcare system and tiered medical treatment system. Relying on strong innovative research capabilities, Zhiwei Microbiology’s multiple rapid diagnostic test kits have entered the registration inspection and clinical trial stages.

[Investor]QingSong Capital, WuHe Investment, Beijing Eternity, PinFeng Medical

【AI+Pathology】Thorough Future, Inc. (referred to as "THORUGH FUTURE") is a company that focuses on artificial intelligence pathology image diagnosis. With artificial intelligence deep learning at its core and typical pathological image features of common tumors as the foundation, it is committed to providing intelligent identification, diagnosis, and prediction for pathology images using big data and artificial intelligence, offering optimal solutions. It serves the pathology community in China and the Asia-Pacific region by promoting the long-term development of digitalization, informatization, and intelligence within the industry.

[Investor]Bangqin Capital, CAS Angel Fund, Korea Investment Partners, RY, Qiming Venture Partners

【Medical SaaS】Future Technology is committed to building enterprise intelligent middleware, helping more enterprises undergo digital transformation through software products, enhancing product capabilities, and improving customer service levels. The "Digital New Infrastructure Platform for Industries" positioning of "Future" accurately captures the core essence of the national digital development strategy, providing strong support for current and future digital construction. Its subsidiary, Neulink, focuses on digital technology and business innovation in the medical industry, constructing a new generation of digital healthcare solutions and ecosystems based on data and business middleware methodologies.

【Investor】Alibaba Cloud, Yuhang National Investment Group, Gingko Valley Capital

【Medical Imaging Services】Yimai Sunshine, initiated by several elites in China's medical imaging industry, is committed to the construction, operation, and management of offline third-party medical imaging centers and medical imaging cloud service platforms. It is currently the company with the largest number of independent medical imaging center licenses in China. Yimai Sunshine Medical Imaging Center focuses on direct investment in high-end large medical equipment and integrates premium expert resources through cloud services provided by a remote medical diagnosis platform, offering medical imaging examination and diagnostic services to medical institutions at all levels and patients. As an industry leader, Yimai Sunshine’s medical imaging center network covers 54 county-level administrative regions across 16 provinces, autonomous regions, and municipalities in China, demonstrating the company’s deep market insight and strategic layout.

【Investors】Undisclosed

【Cell Sorting】Changchun Changguang Chenying Bioscience Instrument Co., Ltd., supported by the cradle of Chinese optics—Changchun Institute of Optics, Fine Mechanics and Physics, Chinese Academy of Sciences, boasts strong research and development capabilities along with industrialization support. Changguang Chenying is committed to solving biological and medical challenges through applied optical technology, developing and manufacturing biomedical instruments of international standards. The core product currently launched by Changguang Chenying is the PRECI SCS Visual Single-Cell Analysis and Sorting Platform, which rapidly identifies target cells/microparticles using AI image recognition, ultra-fast 3D fluorescence analysis, and single-cell Raman ID identification technologies. Not only does it master microfluidics and optical tweezers technologies, but it also innovatively applies Laser Induced Forward Transfer (LIFT), a technology widely used in the materials industry, to commercial cell sorting products for the first time globally. This allows for visualized, precise sorting under a microscope with >99% single-cell yield and purity, achieving a technological breakthrough in this field.

【Investor】Shuimu Ventures, Shunwei Capital, Xiaochi Capital

【Functional Foods】Glue House is a food biotechnology research and development company. It is committed to the research and development of functional active peptides, biopharmaceutical intermediates, functional food ingredients, nutritional health products, and future synthetic biology-related product development support industries. It is an innovative high-tech enterprise integrating scientific research, production, marketing, and comprehensive health services. The financing will be used to accelerate Glue House's R&D progress in the fields of functional foods and biopharmaceuticals, as well as to expand the market and enhance brand influence.

【Investor】Lauxera Capital Partners、Wisconn Valley Ventures